Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $40.00 by Analysts at Mizuho

Sarepta Therapeutics (NASDAQ:SRPT) had its target price trimmed by Mizuho from $85.00 to $40.00 in a research report released on Wednesday,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on SRPT. Needham & Company LLC decreased their price target on Sarepta Therapeutics from $125.00 to $50.00 and set a “buy” rating for the company in a research note on Monday. Morgan Stanley reiterated an “equal weight” rating and issued a $40.00 price target (down from $113.00) on shares of Sarepta Therapeutics in a research note on Monday. TD Cowen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $24.00 price objective on the stock. in a report on Wednesday. Oppenheimer cut their price objective on Sarepta Therapeutics from $184.00 to $123.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Finally, BMO Capital Markets lowered Sarepta Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $120.00 to $70.00 in a report on Monday. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $70.76.

Sarepta Therapeutics Trading Down 3.7%

Sarepta Therapeutics stock opened at $20.77 on Wednesday. The stock has a 50-day moving average of $44.31 and a two-hundred day moving average of $84.36. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. Sarepta Therapeutics has a one year low of $18.30 and a one year high of $173.25. The stock has a market cap of $2.04 billion, a PE ratio of -7.72 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million during the quarter, compared to analysts’ expectations of $685.75 million. During the same quarter last year, the business posted $0.73 earnings per share. The company’s quarterly revenue was up 80.2% compared to the same quarter last year. On average, research analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently bought and sold shares of the business. EP Wealth Advisors LLC boosted its position in Sarepta Therapeutics by 2.2% during the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock worth $606,000 after purchasing an additional 105 shares in the last quarter. CIBC Asset Management Inc boosted its position in Sarepta Therapeutics by 5.1% during the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 139 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock valued at $352,000 after acquiring an additional 145 shares in the last quarter. Virtus ETF Advisers LLC lifted its position in shares of Sarepta Therapeutics by 6.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company’s stock valued at $342,000 after acquiring an additional 174 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its position in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.